PLS

Myelodysplastic Syndromes: Diagnosis and Emerging Therapies

The myelodysplastic syndromes (MDS) are recognized as a growing disease burden in oncology care within the United States. For the first time in the history of this disease, physicians have access to a therapeutic agent with the capacity to impact the natural history of the disease. Understanding the selection of patients, proper counseling on side effects, and the potential for development of combination treatments is paramount for optimizing patient outcomes and further drug development for the treatment of MDS.

Steven D. Gore, MD
Johns Hopkins Medical Institutions

Alan F. List, MD
H. Lee Moffitt Cancer Center and Research Institute

EBMT 2004 - Valganciclovir for CMV Prevention after Stem Cell Transplantation

Strategies for the Prevention of Late CMV Infections After SCT
M. Boeckh
Seattle, USA

Proteomics for Early Prediction of GVHD and CMV Infection
E. M. Mischak-Weissinger
Hannover, Germany

Use of Antiviral Agents Against Other Herpesvirus Infections After SCT
P. Ljungman
Stockholm, Swedenam

BMTR Reviews - Photoimmune Therapy: Expanded Applications for Graft-versus-Host Disease

Extracorporeal Photopheresis Mechanism of Action in GvHD
Francine Foss, MD
Tufts New England Medical Center

Extracorporeal Photopheresis as Part of a Standard Myeloablative
Preparative Regimen to Prevent Acute GvHD
Paul Shaughnessy, MD
Texas Transplant Institute

ECP in Skin and Liver GvHD: The MDACC Experience
Daniel Couriel, MD
M.D. Anderson Cancer Center

Bloodline Reviews 3-1, Advances in Intravenous Immunoglobulin Therapy

Advances in Intravenous Immunoglobulin Therapy: Mechanisms of Action and Clinical Applications
Ronald A. Sacher, MD
University of Cincinnati Medical Center

Confronting the New Challenges in Blood Product Pathogen Safety
Dominique Pifat, PhD
Bayer Corporation, Biological Products Division

Role of FC Receptors in Autoimmune Disease and their Modulation by Intravenous Gammaglobulin
Jeffrey V. Ravetch, MD, PhD The Rockefeller University

Comparison of Different IGIV Preparations in the
Normalization of Platelet Counts in ITP
Anne L. Angiolillo, MD
George Washington University School of Medicine and Health Sciences

Recognizing the Differences in IGIV Production-from Efficacy to Tolerability
Erwin W. Gelfand, MD
University of Colorado Health Sciences Center
Chairman, Department of Pediatrics

Questions & Answers

BMTR Reviews - Novel Applications of Photoimmunotherapy in the Prevention of GvHD

Extracorporeal Photopheresis in the Prevention of GvHD
Francine Foss, MD
Tufts New England Medical Center

Extracorporeal Photopheresis for the Management of Cutaneous Chronic GvHD
Paolo Anderlini, MD
University of Texas MD Anderson Cancer Center

Extracorporeal Photochemotherapy for Pediatric Patients with Acute and Chronic GvHD
Roberto Dall'Amico, MD, PhD
University of Padua School of Medicine

Question & Answer Session

Bloodline Reviews 3-2, Immuno-fine-tuning: Focus on Intravenous Immune Globulin Selection

Pharmaceutical Aspects of IVIG
Jerry Siegel, RPh, FASHP - Session Chair Senior Director, Pharmaceutical Services
Clinical Associate Professor
The Ohio State University Medical Center
College of Pharmacy
Columbus, Ohio

The Cost of Adverse Events: How to Prevent and Treat
Thomas G. Schleis, MS, RPh
Director of Pharmacy
Northwest Medical Specialties
Tacoma,Washington

Expanding Use of IGIV: New Concepts and a Requirement for an Integrated Team Approach
Erwin W. Gelfand, MD
Chairman, Department of Pediatrics
Professor of Pediatrics and Immunology
National Jewish Medical and Research Center
University of Colorado Health Sciences Center
Denver, Colorado

Questions & Answers

BMTR - Impact of CMV in Stem Cell Transplantation

Current Treatment and Prevention Options for CMV
John R. Wingard, MD
University of Florida College of Medicine

CMV Diagnosis and Resistance
Michael Boeckh, MD
Fred Hutchinson Cancer Research Center

Emerging Treatment Options for CMV in Stem Cell Transplantation
W. Garrett Nichols, MD, MS
Fred Hutchinson Cancer Research Center

Question & Answer Session

Bloodline Reviews 1-4, Recombinant Factor VIIa for Bleeding in Surgery and Trauma

The content of this issue of Bloodline Reviews is based on presentations made at the 6th Novo Nordisk Symposium on the Treatment of Bleeding and Thrombotic Disorders, held in May 2001, in Copenhagen, Denmark. The accompanying Private Lecture files contain full versions of the presentations, including audio and slides.

Recombinant Factor VIIa as a Hemostatic Agent
Ula Hedner, MD, PhD

Mechanism of Action of NovoSeven Using a Cell-Based Model
Maureane Hoffman, MD, PhD

Use of Recombinant Factor VIIa in the Post-Injury Period: A Trauma Surgeon's Perspective
Mauricio Lynn, MD

The Use of rFVIIa as an Adjunct Treatment for Hemorrhage Control in Trauma and Surgery
Uri Martinowitz, MD

rFVIIa for Profuse Bleeding in Surgical Patients
Gili Kenet, MD, PhD

The Risk of Bleeding During Liver Surgery and Liver Transplantation and the Effect on Outcome
Robert J. Porte, MD, PhD

Tissue Factor Blockade in Experimental Acute Lung Injury
Karen Welty-Wolf, MD

Safety of Treatment with NovoSeven
Harold Roberts, MD

Reticulocyte Hemoglobin Content and the Diagnosis of Iron Deficiency

Steven Fishbane, MD

Diagnosis of iron deficiency in hemodialysis patients is limited by the inaccuracy of commonly used tests. Reticulocyte hemoglobin content (CHr) is a test that has shown promise for improved diagnosis in preliminary studies. Dr. Fishbane presents data on the use of CHr as a test for iron deficiency in hemodialysis patients.

Beating Heart Surgery: Current Status and Implications for Right Heart Support

Dr. Mitchell Magee

Lecture describes the clinical experience with a mini-support device for CABG surgery that may potentially improve anastomotic access for difficult to access vessels while managing patient hemodynamics and cardiac output.

Is Complete Revascularization Compromised in Off Pump Grafting?

James Edgerton, MD

Welcome to an interactive multimedia lecture brought to you by The Heart Surgery ForumÂ®, in conjunction with Dr. James Edgerton of Medical City Dallas and Medtronic Cardiac Surgery.

Management of Non-Hodgkin's Lymphoma Relapse

Armand Keating, MD

Evidence is reviewed that supports an approach to managing patients who have relapsed or never achieved a remission after front-line chemotherapy for aggressive lymphoma. Also discussed is how intensive therapy and autotransplant can be used in an evidence-based manner to provide the best outcome for these patients.